Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.24 +5.1%	$1.33	$1.05 ▼ $10.16	$37M	1.55	254,707 shs	285,760 shs
GLS Gelesis		$0.21	$0.11 ▼ $5.71	$11.63M	0.88	386,034 shs	185,100 shs
MRSN Mersana Therapeutics	$0.34 +0.3%	$0.36	$0.26 ▼ $2.83	$42.45M	0.83	2.61 million shs	1.11 million shs
NBRV Nabriva Therapeutics		$0.00	$1.22 ▼ $8.45	$45.46M	1.53	29,344 shs	302 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	+5.08%	+2.48%	+5.98%	-52.49%	-80.19%
GLS Gelesis	0.00%	0.00%	0.00%	0.00%	0.00%
MRSN Mersana Therapeutics	+0.29%	-3.34%	-3.04%	-16.70%	-84.54%
NBRV Nabriva Therapeutics	0.00%	0.00%	0.00%	0.00%	+4,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRV Acrivon Therapeutics	3.693 of 5 stars	4.5	5.0	0.0	0.0	0.6	2.5	0.6
GLS Gelesis	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	3.8898 of 5 stars	3.5	4.0	0.0	4.1	0.0	2.5	0.0
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	3.00	Buy	$17.71	1,328.57% Upside
GLS Gelesis	0.00	N/A	N/A	N/A
MRSN Mersana Therapeutics	3.00	Buy	$5.20	1,422.25% Upside
NBRV Nabriva Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest GLS, MRSN, NBRV, and ACRV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	MRSN Mersana Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/16/2025	ACRV Acrivon Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/16/2025	MRSN Mersana Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
5/16/2025	MRSN Mersana Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/15/2025	ACRV Acrivon Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/15/2025	MRSN Mersana Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$3.00
5/6/2025	MRSN Mersana Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$4.00 ➝ $3.00
5/5/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
5/4/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/26/2025	ACRV Acrivon Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/26/2025	ACRV Acrivon Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $19.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$5.68 per share	N/A
GLS Gelesis	$25.77M	0.00	N/A	N/A	($0.34) per share	0.00
MRSN Mersana Therapeutics	$40.50M	1.05	N/A	N/A	($0.08) per share	-4.27
NBRV Nabriva Therapeutics	$35.59M	0.00	N/A	N/A	$0.10 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$80.56M	-$2.22	N/A	N/A	N/A	N/A	-44.66%	-40.94%	8/12/2025 (Estimated)
GLS Gelesis	-$56.03M	-$1.40	N/A	N/A	N/A	-221.38%	N/A	-14.98%	N/A
MRSN Mersana Therapeutics	-$69.19M	-$0.59	N/A	N/A	N/A	-217.63%	-990.16%	-48.87%	8/12/2025 (Estimated)
NBRV Nabriva Therapeutics	-$57.19M	-$19.20	N/A	N/A	N/A	-148.11%	-365.53%	-135.81%	N/A

Latest GLS, MRSN, NBRV, and ACRV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	MRSN Mersana Therapeutics	-$0.21	-$0.19	+$0.02	-$0.19	$6.05 million	$2.75 million
5/13/2025	Q1 2025	ACRV Acrivon Therapeutics	-$0.57	-$0.51	+$0.06	-$0.51	N/A	N/A
3/27/2025	Q4 2024	ACRV Acrivon Therapeutics	-$0.69	-$0.60	+$0.09	-$0.60	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
GLS Gelesis	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	N/A	N/A	N/A	N/A
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	11.17	11.17
GLS Gelesis	N/A	0.30	0.21
MRSN Mersana Therapeutics	13.35	1.83	1.83
NBRV Nabriva Therapeutics	0.12	0.85	0.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
GLS Gelesis	16.71%
MRSN Mersana Therapeutics	93.92%
NBRV Nabriva Therapeutics	0.27%

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	8.50%
GLS Gelesis	11.90%
MRSN Mersana Therapeutics	13.00%
NBRV Nabriva Therapeutics	1.63%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	58	31.35 million	28.69 million	Not Optionable
GLS Gelesis	2	73.33 million	64.61 million	Not Optionable
MRSN Mersana Therapeutics	150	124.63 million	108.43 million	Optionable
NBRV Nabriva Therapeutics	70	32.02 million	31.49 million	Not Optionable

GLS, MRSN, NBRV, and ACRV Headlines

Recent News About These Companies

Nabriva Therapeutics plc (NBRVF)

October 19, 2024 | finance.yahoo.com

Meitheal gains rights to Contempo

July 20, 2024 | thepharmaletter.com

Meitheal gains rights to CONTEPO from Nabriva in North America

July 19, 2024 | pharmaceutical-technology.com

Nabriva Therapeutics PLC NBRVF

April 13, 2024 | morningstar.com

Nabriva Therapeutics files patent for a dosing regimen for fosfomycin treatment

December 22, 2023 | pharmaceutical-technology.com

Arbutus Biopharma Corporation: Arbutus Appoints Two New Executives

July 11, 2023 | finanznachrichten.de

NBRV - Nabriva Therapeutics plc

May 26, 2023 | finance.yahoo.com

Bacterial Pneumonia Therapeutics Market Updated Report by Competitor Strategics till 2029

February 28, 2023 | marketwatch.com

NBRV Nabriva Therapeutics plc

February 25, 2023 | seekingalpha.com

Nabriva Therapeutics Provides Corporate Update

January 6, 2023 | finance.yahoo.com

Nabriva Therapeutics Shares Rise 11% After Positive Xenleta Trial Data

November 28, 2022 | marketwatch.com

Nabriva Adds 9% On Positive Results From Study Of Xenleta In Cystic Fibrosis

November 28, 2022 | markets.businessinsider.com

Nabriva Announces Positive Results From Phase 1 Trial Of Lefamulin In Cystic Fibrosis; Stock Up

November 28, 2022 | markets.businessinsider.com

Nabriva stock up after firm's antibiotic shows promise as a potential cystic fibrosis treatment

November 28, 2022 | bizjournals.com

Nabriva gains after announcing Phase 1 data for cystic fibrosis candidate

November 28, 2022 | seekingalpha.com

Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

November 28, 2022 | finance.yahoo.com

Nabriva's stock is up after sharing antibiotic news

November 28, 2022 | finance.yahoo.com

Nabriva's antibiotic shows promise as a potential cystic fibrosis treatment

November 28, 2022 | finance.yahoo.com

Nabriva Therapeutics describes new 12-epi-mutilin compounds to treat bacterial infections

November 10, 2022 | bioworld.com

Montgomery County biopharmaceutical firm reducing workforce by 40%

November 10, 2022 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLS, MRSN, NBRV, and ACRV Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.24 +0.06 (+5.08%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$1.26 +0.02 (+2.02%)

As of 06/24/2025 07:55 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Gelesis NYSE:GLS

Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Mersana Therapeutics NASDAQ:MRSN

$0.34 +0.00 (+0.29%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$0.35 +0.01 (+2.17%)

As of 04:39 AM Eastern

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Nabriva Therapeutics NASDAQ:NBRV

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time